Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Free Cash Flow (2018 - 2025)

Serina Therapeutics' Free Cash Flow history spans 8 years, with the latest figure at -$3.8 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 28.6% year-over-year to -$3.8 million; the TTM value through Sep 2025 reached -$16.5 million, down 37.02%, while the annual FY2024 figure was -$17.1 million, 579.44% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$3.8 million at Serina Therapeutics, roughly flat from -$3.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $511000.0 in Q4 2023 and bottomed at -$8.0 million in Q2 2024.
  • The 5-year median for Free Cash Flow is -$1.6 million (2021), against an average of -$2.4 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 138.68% in 2023 before it crashed 991.78% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$1.6 million in 2021, then increased by 19.79% to -$1.3 million in 2022, then surged by 138.68% to $511000.0 in 2023, then plummeted by 991.78% to -$4.6 million in 2024, then grew by 16.33% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Free Cash Flow are -$3.8 million (Q3 2025), -$3.8 million (Q2 2025), and -$4.3 million (Q1 2025).